Soluble SLAMF7 promotes the growth of myeloma cells via homophilic interaction with surface SLAMF7
出版年份 2019 全文链接
标题
Soluble SLAMF7 promotes the growth of myeloma cells via homophilic interaction with surface SLAMF7
作者
关键词
-
出版物
LEUKEMIA
Volume -, Issue -, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2019-07-29
DOI
10.1038/s41375-019-0525-6
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Cancer statistics, 2019
- (2019) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Cancer cell-expressed SLAMF7 is not required for CD47-mediated phagocytosis
- (2019) Yuan He et al. Nature Communications
- Myeloma Cells Are Activated in Bone Marrow Microenvironment by the CD180/MD-1 Complex, Which Senses Lipopolysaccharide
- (2018) Jiro Kikuchi et al. CANCER RESEARCH
- Antibody-Dependent Cellular Phagocytosis by Macrophages is a Novel Mechanism of Action of Elotuzumab
- (2018) Ahmed T. Kurdi et al. MOLECULAR CANCER THERAPEUTICS
- SHP2 is required for growth of KRAS-mutant non-small-cell lung cancer in vivo
- (2018) Sara Mainardi et al. NATURE MEDICINE
- Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma
- (2018) María-Victoria Mateos et al. NEW ENGLAND JOURNAL OF MEDICINE
- Daratumumab, lenalidomide, and dexamethasone in East Asian patients with relapsed or refractory multiple myeloma: subgroup analyses of the phase 3 POLLUX study
- (2018) Kenshi Suzuki et al. Blood Cancer Journal
- ELOTUZUMAB FOR THE TREATMENT OF RELAPSED OR REFRACTORY MULTIPLE MYELOMA, WITH SPECIAL REFERENCE TO ITS MODES OF ACTION AND SLAMF7 SIGNALING
- (2018) Masafumi Taniwaki et al. Mediterranean Journal of Hematology and Infectious Diseases
- IMiDs through loss of Ikaros and Aiolos primes myeloma cells for daratumumab mediated killing by upregulation of CD38
- (2018) Pasquale L. Fedele et al. BLOOD
- Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma
- (2018) Meletios A. Dimopoulos et al. NEW ENGLAND JOURNAL OF MEDICINE
- SHP2 is required for BCR-ABL1-induced hematologic neoplasia
- (2017) S Gu et al. LEUKEMIA
- Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study
- (2017) S K Kumar et al. LEUKEMIA
- Monoclonal antibody therapy in multiple myeloma
- (2017) C Touzeau et al. LEUKEMIA
- SLAMF7 is critical for phagocytosis of haematopoietic tumour cells via Mac-1 integrin
- (2017) Jun Chen et al. NATURE
- Development and Validation of Electrochemiluminescence Assays to Measure Free and Total sSLAMF7 in Human Serum in the Absence and Presence of Elotuzumab
- (2016) Jennifer Postelnek et al. AAPS Journal
- Randomized phase 2 study: elotuzumab plus bortezomib/dexamethasone vs bortezomib/dexamethasone for relapsed/refractory MM
- (2016) A. Jakubowiak et al. BLOOD
- Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myeloma
- (2016) N. Weinhold et al. BLOOD
- SLAM family receptors in normal immunity and immune pathologies
- (2016) Ning Wu et al. CURRENT OPINION IN IMMUNOLOGY
- Blimp-1/PRDM1 regulates the transcription of human CS1 (SLAMF7) gene in NK and B cells
- (2016) Jong R. Kim et al. IMMUNOBIOLOGY
- Elotuzumab with lenalidomide and dexamethasone for Japanese patients with relapsed/refractory multiple myeloma: phase 1 study
- (2016) Shinsuke Iida et al. INTERNATIONAL JOURNAL OF HEMATOLOGY
- Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma
- (2016) Meletios A. Dimopoulos et al. NEW ENGLAND JOURNAL OF MEDICINE
- Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma
- (2016) Antonio Palumbo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Molecular pathogenesis of multiple myeloma
- (2015) Yusuke Furukawa et al. International Journal of Clinical Oncology
- Phosphorylation-mediated EZH2 inactivation promotes drug resistance in multiple myeloma
- (2015) Jiro Kikuchi et al. JOURNAL OF CLINICAL INVESTIGATION
- Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma
- (2015) Sagar Lonial et al. NEW ENGLAND JOURNAL OF MEDICINE
- Rate of CRL4CRBN substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF4
- (2015) C C Bjorklund et al. Blood Cancer Journal
- Trends of survival in patients with multiple myeloma in Japan: a multicenter retrospective collaborative study of the Japanese Society of Myeloma
- (2015) S Ozaki et al. Blood Cancer Journal
- Plasma Membrane Proteomics Identifies Biomarkers Associated with MMSET Overexpression in T(4;14) Multiple Myeloma
- (2015) Zhigang Xie et al. Oncotarget
- Immune Cell Inhibition by SLAMF7 Is Mediated by a Mechanism Requiring Src Kinases, CD45, and SHIP-1 That Is Defective in Multiple Myeloma Cells
- (2014) Huaijian Guo et al. MOLECULAR AND CELLULAR BIOLOGY
- Elotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation: evidence for augmented NK cell function complementing ADCC
- (2013) Shauna M. Collins et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients
- (2013) S K Kumar et al. LEUKEMIA
- Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells
- (2013) J. Kronke et al. SCIENCE
- The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins
- (2013) G. Lu et al. SCIENCE
- A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma
- (2011) J. A. Zonder et al. BLOOD
- Histone deacetylases are critical targets of bortezomib-induced cytotoxicity in multiple myeloma
- (2010) J. Kikuchi et al. BLOOD
- Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma
- (2009) F. van Rhee et al. MOLECULAR CANCER THERAPEUTICS
- Essential function for SAP family adaptors in the surveillance of hematopoietic cells by natural killer cells
- (2009) Zhongjun Dong et al. NATURE IMMUNOLOGY
- Lenalidomide down-regulates the CD20 antigen and antagonizes direct and antibody-dependent cellular cytotoxicity of rituximab on primary chronic lymphocytic leukemia cells
- (2008) R. Lapalombella et al. BLOOD
- CS1, a Potential New Therapeutic Antibody Target for the Treatment of Multiple Myeloma
- (2008) E. D. Hsi et al. CLINICAL CANCER RESEARCH
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation